Our News on Newswise

Spark Therapeutics and Pfizer Announce Publication in The New England Journal of Medicine of Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Hemophilia B

Spark Therapeutics (NASDAQ: ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, and Pfizer Inc. (NYSE:PFE), today announced that The New England Journal of Medicine has published interim data...
6-Dec-2017 5:00 PM EST Add to Favorites

Spark Therapeutics Announces Publication in The Lancet of Pivotal Phase 3 Clinical Trial Data for Investigational Voretigene Neparvovec

Spark Therapeutics announces publication in The Lancet of pivotal Phase 3 data at year one for investigational voretigene neparvovec an investigational, potential one-time gene therapy candidate for the treatment of patients with vision loss due to...
13-Jul-2017 6:30 PM EDT Add to Favorites

See All News

Our Experts on Newswise

Our experts are coming soon...


About section not configured. Is this your member page? Login to edit, or contact member@newswise.com to configure this module.


Denise Bradley
Head of Corporate Communications and Community Engagement · Spark Therapeutics, Inc.